Tags

Type your tag names separated by a space and hit enter

Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.
Curr Atheroscler Rep. 2007 Nov; 9(5):359-66.CA

Abstract

Rimonabant is a selective blocker of the CB(1) cannabinoid receptor that has been developed for treatment of abdominal obesity, dyslipidemia, and control of diabetes. Four randomized clinical trials have demonstrated that following 1 year of treatment, 20 mg/d of rimonabant is associated with greater weight loss and reduction in waist circumference compared with placebo. Therapy with rimonabant is associated with favorable changes in serum high-density lipoprotein and triglycerides, as well as with an improvement in glycemic control among obese type 2 diabetic patients. Rimonabant appears to be well tolerated, with the most common side effects being nausea, anxiety, and depressive symptoms. Rimonabant is a novel agent that has the potential to be a useful adjunct to lifestyle and behavior modification in treatment of abdominal obesity, dyslipidemia, and dysglycemia.

Authors+Show Affiliations

Beth Israel Deaconess Medical Center, Boston, MA, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

18001618

Citation

Dibble, Christopher T., et al. "Rimonabant: the Role of Endocannabinoid Type 1 Receptor Antagonism in Modulating the Weight and Lipid Profile of Obese Patients." Current Atherosclerosis Reports, vol. 9, no. 5, 2007, pp. 359-66.
Dibble CT, Gelfand EV, Cannon CP. Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients. Curr Atheroscler Rep. 2007;9(5):359-66.
Dibble, C. T., Gelfand, E. V., & Cannon, C. P. (2007). Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients. Current Atherosclerosis Reports, 9(5), 359-66.
Dibble CT, Gelfand EV, Cannon CP. Rimonabant: the Role of Endocannabinoid Type 1 Receptor Antagonism in Modulating the Weight and Lipid Profile of Obese Patients. Curr Atheroscler Rep. 2007;9(5):359-66. PubMed PMID: 18001618.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients. AU - Dibble,Christopher T, AU - Gelfand,Eli V, AU - Cannon,Christopher P, PY - 2007/11/16/pubmed PY - 2008/3/15/medline PY - 2007/11/16/entrez SP - 359 EP - 66 JF - Current atherosclerosis reports JO - Curr Atheroscler Rep VL - 9 IS - 5 N2 - Rimonabant is a selective blocker of the CB(1) cannabinoid receptor that has been developed for treatment of abdominal obesity, dyslipidemia, and control of diabetes. Four randomized clinical trials have demonstrated that following 1 year of treatment, 20 mg/d of rimonabant is associated with greater weight loss and reduction in waist circumference compared with placebo. Therapy with rimonabant is associated with favorable changes in serum high-density lipoprotein and triglycerides, as well as with an improvement in glycemic control among obese type 2 diabetic patients. Rimonabant appears to be well tolerated, with the most common side effects being nausea, anxiety, and depressive symptoms. Rimonabant is a novel agent that has the potential to be a useful adjunct to lifestyle and behavior modification in treatment of abdominal obesity, dyslipidemia, and dysglycemia. SN - 1523-3804 UR - https://www.unboundmedicine.com/medline/citation/18001618/Rimonabant:_the_role_of_endocannabinoid_type_1_receptor_antagonism_in_modulating_the_weight_and_lipid_profile_of_obese_patients_ L2 - https://medlineplus.gov/metabolicsyndrome.html DB - PRIME DP - Unbound Medicine ER -